{"protocolSection": {"identificationModule": {"nctId": "NCT00867490", "orgStudyIdInfo": {"id": "CSPH100ADE01"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Safety and Efficacy of Aliskiren + Hydrochlorothiazide (\u00b1 Amlodipine 5 mg) in Patients With Moderate Hypertension", "officialTitle": "An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With Aliskiren 300 mg Plus Hydrochlorothiazide 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With Candesartan 32 mg Plus Hydrochlorothiazide 25 mg", "acronym": "AMAZING"}, "statusModule": {"statusVerifiedDate": "2011-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-03"}, "primaryCompletionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-03-20", "studyFirstSubmitQcDate": "2009-03-20", "studyFirstPostDateStruct": {"date": "2009-03-23", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-01-07", "resultsFirstSubmitQcDate": "2011-01-07", "resultsFirstPostDateStruct": {"date": "2011-02-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-05-04", "lastUpdatePostDateStruct": {"date": "2011-05-06", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study will assess the safety and efficacy of aliskiren plus hydrochlorothiazide (HCTZ) in patients who do not achieve controlled blood pressure levels after treatment with another specified antihypertensive medication. There was an optional study extension for the first eligible 60 patients who wanted to participate that contains the triple therapy with amlodipine 5 mg and aliskiren 300 mg plus HCTZ 25 mg.", "detailedDescription": "Title of study extension: An open-label, multicenter extension to evaluate the efficacy and safety of a 4 week therapy with amlodipine 5 mg and aliskiren 300 mg plus HCTZ 25 mg in hypertensive patients not adequately responding to a 4 week therapy each with the combinations of candesartan 32 mg plus hydrochlorothiazide 25 mg followed by aliskiren 300mg plus hydrochlorothiazide 25 mg"}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Hypertension", "aliskiren", "cardiovascular diseases"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 186, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Candesartan+HCTZ, aliskiren+HCTZ, aliskiren+HCTZ+amlodipine", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Candesartan+HCTZ - Phase 1", "Drug: Aliskiren+HCTZ - Phase 2", "Drug: Aliskiren+HCTZ+amlodipine - Phase 3"]}], "interventions": [{"type": "DRUG", "name": "Candesartan+HCTZ - Phase 1", "description": "4 weeks treatment with candesartan 32 mg (two 16 mg tablets) plus hydrochlorothiazide 25 mg (two 12.5 mg tablets) taken orally with water in the morning between 7 and 10 am.", "armGroupLabels": ["Candesartan+HCTZ, aliskiren+HCTZ, aliskiren+HCTZ+amlodipine"]}, {"type": "DRUG", "name": "Aliskiren+HCTZ - Phase 2", "description": "Patients with uncontrolled mean sitting diastolic blood pressure (msDBP \u2265 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am.", "armGroupLabels": ["Candesartan+HCTZ, aliskiren+HCTZ, aliskiren+HCTZ+amlodipine"]}, {"type": "DRUG", "name": "Aliskiren+HCTZ+amlodipine - Phase 3", "description": "The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP \u2265 90 mm Hg and/or msSBP \u2265 140 mm Hg) at the end of Phase 2 were offered 4 weeks treatment with aliskiren 300 mg plus HCTZ 25 mg in a single tablet plus an amlodipine 5 mg tablet taken orally with water in the morning between 7 and 10 am.", "armGroupLabels": ["Candesartan+HCTZ, aliskiren+HCTZ, aliskiren+HCTZ+amlodipine"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.", "timeFrame": "Baseline Phase 2 to end of Phase 2"}, {"measure": "Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.", "timeFrame": "Baseline Phase 3 to end of Phase 3"}], "secondaryOutcomes": [{"measure": "Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Core Phase of the Study", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.", "timeFrame": "Baseline Phase 2 to end of Phase 2"}, {"measure": "Change in Sitting Pulse Pressure During the Core Phase of the Study", "description": "Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.", "timeFrame": "Baseline Phase 2 to end of Phase 2"}, {"measure": "Change in Sitting Pulse Rate During the Core Phase of the Study", "description": "Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position.", "timeFrame": "Baseline Phase 2 to end of Phase 2"}, {"measure": "Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study", "description": "Normalized blood pressure was defined as a msSBP \\< 140 mmHg and/or a msDBP \\< 90 mmHg.", "timeFrame": "Baseline Phase 2 to end of Phase 2"}, {"measure": "Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study", "description": "Blood pressure response was defined as msSBP \\< 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 2 compared to Baseline in Phase 2 or a msDBP \\< 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 2 compared to Baseline in Phase 2.", "timeFrame": "Baseline Phase 2 to end of Phase 2"}, {"measure": "Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Extension Phase of the Study", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.", "timeFrame": "Baseline Phase 3 to end of Phase 3"}, {"measure": "Change in Sitting Pulse Pressure During the Extension Phase of the Study", "description": "Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.", "timeFrame": "Baseline Phase 3 to end of Phase 3"}, {"measure": "Change in Sitting Pulse Rate During the Extension Phase of the Study", "description": "Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position.", "timeFrame": "Baseline Phase 3 to end of Phase 3"}, {"measure": "Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study", "description": "Normalized was defined as a msSBP \\< 140 mm Hg and/or a msDBP \\< 90 mm Hg.", "timeFrame": "Baseline Phase 3 to end of Phase 3"}, {"measure": "Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study", "description": "Blood pressure response was defined as msSBP \\< 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 2 compared to Baseline in Phase 2 or a msDBP \\< 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 2 compared to Baseline in Phase 2.", "timeFrame": "Baseline Phase 3 to end of Phase 3"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria for Core Study:\n\n- Patients with mean sitting diastolic blood pressure \u2265 100 mmHg and \\< 110 mmHg\n\nInclusion criteria for the Extension:\n\n- msSBP \u2265 140 mm Hg and/or msDBP \u2265 90 mm Hg at Visit 5 of the core study\n\nExclusion Criteria for Core Study:\n\n* Patients with mean diastolic blood pressure \u2265 110 mmHg or mean systolic blood pressure \u2265 180 mmHg\n* Patients with prior stroke, hypertensive encephalopathy or heart attack\n* Patients with type 1 diabetes mellitus\n* Patients with type 2 diabetes mellitus with poor glucose control\n\nExclusion criteria for the Extension:\n\n* Premature discontinuation in the core study or failure to comply with the core study protocol\n* History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures, known or suspected contraindications to diuretics as described in the SmPC (particularly amlodipine 5 mg), e.g. severe hypotension, shock - including cardiogenic shock, obstructions impairing the flow out of the left ventricle (e.g. significant aortic stenosis)\n* Any patient that the investigator decides should not participate in the extension study for medical reasons\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis", "affiliation": "Novartis", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Investigative Site", "city": "Chemnitz", "country": "Germany", "geoPoint": {"lat": 50.8357, "lon": 12.92922}}]}, "referencesModule": {"references": [{"pmid": "21117946", "type": "DERIVED", "citation": "Schweizer J, Ulmer HJ, Benduhn H, Klebs S. Efficacy and tolerability of aliskiren 300 mg/hydrochlorothiazide 25 mg (+/- amlodipine 5 mg) in hypertensive patients not controlled by candesartan 32 mg plus HCT 25 mg. Curr Med Res Opin. 2011 Jan;27(1):131-40. doi: 10.1185/03007995.2010.537318. Epub 2010 Nov 30."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Candesartan+HCTZ, Aliskiren+HCTZ, Aliskiren+HCTZ+Amlodipine", "description": "4 weeks treatment with candesartan 32 mg plus hydrochlorothiazide (HCTZ) 25 mg (Phase 1) followed by 4 weeks treatment with aliskiren 300 mg plus HCTZ 25 mg (Phase 2) in patients with uncontrolled diastolic blood pressure (BP) in Phase 1 followed by (optional) 4 weeks treatment with aliskiren 300 mg plus HCTZ 25 mg plus amlodipine 5 mg (Phase 3) in patients with uncontrolled systolic or diastolic BP in Phase 2."}], "periods": [{"title": "Phase 1 - Candesartan+HCTZ", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "186"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "176"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "5"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "Administrative Problems", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}, {"title": "Phase 2 - Aliskiren+HCTZ", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Only patients with mean sitting diastolic BP \u2265 90 mmHg at the end of Phase 1 entered this phase.", "numSubjects": "123"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "120"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}, {"title": "Phase 3 - Aliskiren+HCTZ+Amlodipine", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "The first 60 patients with systolic BP \u2265 140 mmHg or diastolic BP \u2265 90 mmHg entered this phase.", "numSubjects": "61"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "61"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Candesartan+HCTZ, Aliskiren+HCTZ, Aliskiren+HCTZ+Amlodipine", "description": "4 weeks treatment with candesartan 32 mg plus hydrochlorothiazide (HCTZ) 25 mg (Phase 1) followed by 4 weeks treatment with aliskiren 300 mg plus HCTZ 25 mg (Phase 2) in patients with uncontrolled diastolic blood pressure (BP) in Phase 1 followed by (optional) 4 weeks treatment with aliskiren 300 mg plus HCTZ 25 mg plus amlodipine 5 mg (Phase 3) in patients with uncontrolled systolic or diastolic BP in Phase 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "186"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"title": "Phase I - Candesartan+HCTZ", "categories": [{"measurements": [{"groupId": "BG000", "value": "56.2", "spread": "10.62"}]}]}, {"title": "Phase II - Aliskiren+HCTZ", "categories": [{"measurements": [{"groupId": "BG000", "value": "57.4", "spread": "10.87"}]}]}, {"title": "Phase III - Aliskiren+HCTZ+amlodipine", "categories": [{"measurements": [{"groupId": "BG000", "value": "58.9", "spread": "10.31"}]}]}]}, {"title": "Sex/Gender, Customized", "description": "Female", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Phase I - Candesartan+HCTZ", "categories": [{"measurements": [{"groupId": "BG000", "value": "78"}]}]}, {"title": "Phase II - Aliskiren+HCTZ", "categories": [{"measurements": [{"groupId": "BG000", "value": "48"}]}]}, {"title": "Phase III - Aliskiren+HCTZ+amlodipine", "categories": [{"measurements": [{"groupId": "BG000", "value": "24"}]}]}]}, {"title": "Sex/Gender, Customized", "description": "Male", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Phase I - Candesartan+HCTZ", "categories": [{"measurements": [{"groupId": "BG000", "value": "108"}]}]}, {"title": "Phase II - Aliskiren+HCTZ", "categories": [{"measurements": [{"groupId": "BG000", "value": "75"}]}]}, {"title": "Phase III - Aliskiren+HCTZ+amlodipine", "categories": [{"measurements": [{"groupId": "BG000", "value": "37"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.", "populationDescription": "Intent-to-treat population (ITT): All patients who took at least one dose of aliskiren plus HCTZ who had at least one primary efficacy parameter evaluation. Patients who dropped out were included in the ITT population if there was any BP measurement available; their last available blood pressure measurement was used for the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline Phase 2 to end of Phase 2", "groups": [{"id": "OG000", "title": "Phase 2 - Aliskiren+HCTZ", "description": "Patients with uncontrolled mean sitting diastolic BP (msDBP \u2265 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide (HCTZ) 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.12", "lowerLimit": "-4.29", "upperLimit": "-1.95"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Core Phase of the Study", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.", "populationDescription": "Intent-to-treat population (ITT): All patients who took at least one dose of aliskiren plus HCTZ who had at least one primary efficacy parameter evaluation. Patients who dropped out were included in the ITT population if there was any BP measurement available; their last available blood pressure measurement was used for the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline Phase 2 to end of Phase 2", "groups": [{"id": "OG000", "title": "Phase 2 - Aliskiren+HCTZ", "description": "Patients with uncontrolled mean sitting diastolic BP (msDBP \u2265 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide (HCTZ) 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.81", "lowerLimit": "-4.81", "upperLimit": "-0.81"}]}]}]}, {"type": "SECONDARY", "title": "Change in Sitting Pulse Pressure During the Core Phase of the Study", "description": "Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.", "populationDescription": "Intent-to-treat population (ITT): All patients who took at least one dose of aliskiren plus HCTZ who had at least one primary efficacy parameter evaluation. Patients who dropped out were included in the ITT population if there was any BP measurement available; their last available blood pressure measurement was used for the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline Phase 2 to end of Phase 2", "groups": [{"id": "OG000", "title": "Phase 2 - Aliskiren+HCTZ", "description": "Patients with uncontrolled mean sitting diastolic BP (msDBP \u2265 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide (HCTZ) 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.31", "lowerLimit": "-1.39", "upperLimit": "2.01"}]}]}]}, {"type": "SECONDARY", "title": "Change in Sitting Pulse Rate During the Core Phase of the Study", "description": "Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position.", "populationDescription": "Intent-to-treat population (ITT): All patients who took at least one dose of aliskiren plus HCTZ who had at least one primary efficacy parameter evaluation. Patients who dropped out were included in the ITT population if there was any BP measurement available; their last available blood pressure measurement was used for the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "BPM (beats per minute)", "timeFrame": "Baseline Phase 2 to end of Phase 2", "groups": [{"id": "OG000", "title": "Phase 2 - Aliskiren+HCTZ", "description": "Patients with uncontrolled mean sitting diastolic BP (msDBP \u2265 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide (HCTZ) 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.27", "lowerLimit": "-1.15", "upperLimit": "1.69"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study", "description": "Normalized blood pressure was defined as a msSBP \\< 140 mmHg and/or a msDBP \\< 90 mmHg.", "populationDescription": "Intent-to-treat population (ITT): All patients who took at least one dose of aliskiren plus HCTZ who had at least one primary efficacy parameter evaluation. Patients who dropped out were included in the ITT population if there was any BP measurement available; their last available blood pressure measurement was used for the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Baseline Phase 2 to end of Phase 2", "groups": [{"id": "OG000", "title": "Phase 2 - Aliskiren+HCTZ", "description": "Patients with uncontrolled mean sitting diastolic BP (msDBP \u2265 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide (HCTZ) 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}]}], "classes": [{"title": "msSBP < 140 mmHg", "categories": [{"measurements": [{"groupId": "OG000", "value": "37.4"}]}]}, {"title": "msDBP < 90 mmHg", "categories": [{"measurements": [{"groupId": "OG000", "value": "33.3"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study", "description": "Blood pressure response was defined as msSBP \\< 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 2 compared to Baseline in Phase 2 or a msDBP \\< 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 2 compared to Baseline in Phase 2.", "populationDescription": "Intent-to-treat population (ITT): All patients who took at least one dose of aliskiren plus HCTZ who had at least one primary efficacy parameter evaluation. Patients who dropped out were included in the ITT population if there was any BP measurement available; their last available blood pressure measurement was used for the analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Baseline Phase 2 to end of Phase 2", "groups": [{"id": "OG000", "title": "Phase 2 - Aliskiren+HCTZ", "description": "Patients with uncontrolled mean sitting diastolic BP (msDBP \u2265 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide (HCTZ) 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}]}], "classes": [{"title": "msSBP response", "categories": [{"measurements": [{"groupId": "OG000", "value": "37.4"}]}]}, {"title": "msDBP response", "categories": [{"measurements": [{"groupId": "OG000", "value": "34.1"}]}]}]}, {"type": "PRIMARY", "title": "Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.", "populationDescription": "Safety population: All patients who took at least one dose of aliskiren 300 mg plus HCTZ 25 mg plus amlodipine 5 mg.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline Phase 3 to end of Phase 3", "groups": [{"id": "OG000", "title": "Phase III - Aliskiren+HCTZ+Amlodipine", "description": "The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP \u2265 90 mm Hg and/or msSBP \u2265 140 mm Hg) at the end of Phase 2 were offered a 4 week treatment extension with aliskiren 300 mg plus hydrochlorothiazide (HCTZ) 25 mg in a single tablet plus amlodipine 5 mg tablet."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.87", "lowerLimit": "-7.48", "upperLimit": "-4.26"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Extension Phase of the Study", "description": "The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.", "populationDescription": "Safety population: All patients who took at least one dose of aliskiren 300 mg plus HCTZ 25 mg plus amlodipine 5 mg.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline Phase 3 to end of Phase 3", "groups": [{"id": "OG000", "title": "Phase III - Aliskiren+HCTZ+Amlodipine", "description": "The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP \u2265 90 mm Hg and/or msSBP \u2265 140 mm Hg) at the end of Phase 2 were offered a 4 week treatment extension with aliskiren 300 mg plus hydrochlorothiazide (HCTZ) 25 mg in a single tablet plus amlodipine 5 mg tablet."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.20", "lowerLimit": "-11.86", "upperLimit": "-6.54"}]}]}]}, {"type": "SECONDARY", "title": "Change in Sitting Pulse Pressure During the Extension Phase of the Study", "description": "Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.", "populationDescription": "Safety population: All patients who took at least one dose of aliskiren 300 mg plus HCTZ 25 mg plus amlodipine 5 mg.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline Phase 3 to end of Phase 3", "groups": [{"id": "OG000", "title": "Phase III - Aliskiren+HCTZ+Amlodipine", "description": "The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP \u2265 90 mm Hg and/or msSBP \u2265 140 mm Hg) at the end of Phase 2 were offered a 4 week treatment extension with aliskiren 300 mg plus hydrochlorothiazide (HCTZ) 25 mg in a single tablet plus amlodipine 5 mg tablet."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.33", "lowerLimit": "-5.40", "upperLimit": "-1.27"}]}]}]}, {"type": "SECONDARY", "title": "Change in Sitting Pulse Rate During the Extension Phase of the Study", "description": "Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position.", "populationDescription": "Safety population: All patients who took at least one dose of aliskiren 300 mg plus HCTZ 25 mg plus amlodipine 5 mg.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "BPM (beats per minute)", "timeFrame": "Baseline Phase 3 to end of Phase 3", "groups": [{"id": "OG000", "title": "Phase III - Aliskiren+HCTZ+Amlodipine", "description": "The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP \u2265 90 mm Hg and/or msSBP \u2265 140 mm Hg) at the end of Phase 2 were offered a 4 week treatment extension with aliskiren 300 mg plus hydrochlorothiazide (HCTZ) 25 mg in a single tablet plus amlodipine 5 mg tablet."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.03", "lowerLimit": "-1.82", "upperLimit": "1.89"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study", "description": "Normalized was defined as a msSBP \\< 140 mm Hg and/or a msDBP \\< 90 mm Hg.", "populationDescription": "Safety population: All patients who took at least one dose of aliskiren 300 mg plus HCTZ 25 mg plus amlodipine 5 mg.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Baseline Phase 3 to end of Phase 3", "groups": [{"id": "OG000", "title": "Phase III - Aliskiren+HCTZ+Amlodipine", "description": "The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP \u2265 90 mm Hg and/or msSBP \u2265 140 mm Hg) at the end of Phase 2 were offered a 4 week treatment extension with aliskiren 300 mg plus hydrochlorothiazide (HCTZ) 25 mg in a single tablet plus amlodipine 5 mg tablet."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}]}], "classes": [{"title": "msSBP < 140 mmHg", "categories": [{"measurements": [{"groupId": "OG000", "value": "54.1"}]}]}, {"title": "msDBP < 90 mmHg", "categories": [{"measurements": [{"groupId": "OG000", "value": "44.3"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study", "description": "Blood pressure response was defined as msSBP \\< 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 2 compared to Baseline in Phase 2 or a msDBP \\< 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 2 compared to Baseline in Phase 2.", "populationDescription": "Safety population: All patients who took at least one dose of aliskiren 300 mg plus HCTZ 25 mg plus amlodipine 5 mg.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Baseline Phase 3 to end of Phase 3", "groups": [{"id": "OG000", "title": "Phase III - Aliskiren+HCTZ+Amlodipine", "description": "The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP \u2265 90 mm Hg and/or msSBP \u2265 140 mm Hg) at the end of Phase 2 were offered a 4 week treatment extension with aliskiren 300 mg plus hydrochlorothiazide (HCTZ) 25 mg in a single tablet plus amlodipine 5 mg tablet."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}]}], "classes": [{"title": "msSBP response", "categories": [{"measurements": [{"groupId": "OG000", "value": "54.1"}]}]}, {"title": "msDBP response", "categories": [{"measurements": [{"groupId": "OG000", "value": "47.5"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Phase 1 - Candesartan+HCTZ", "description": "4 weeks treatment with candesartan 32 mg (two 16 mg tablets) plus hydrochlorothiazide (HCTZ) 25 mg (two 12.5 mg tablets) taken orally with water in the morning between 7 and 10 am.", "seriousNumAffected": 1, "seriousNumAtRisk": 186, "otherNumAffected": 0, "otherNumAtRisk": 186}, {"id": "EG001", "title": "Phase 2 - Aliskiren+HCTZ", "description": "Patients with uncontrolled mean sitting diastolic BP (msDBP \u2265 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide (HCTZ) 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am.", "seriousNumAffected": 2, "seriousNumAtRisk": 123, "otherNumAffected": 0, "otherNumAtRisk": 123}, {"id": "EG002", "title": "Phase 3 - Aliskiren+HCTZ+Amlodipine", "description": "The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP \u2265 90 mm Hg and/or msSBP \u2265 140 mm Hg) at the end of Phase 2 were offered a 4 week treatment extension with aliskiren 300 mg plus hydrochlorothiazide (HCTZ) 25 mg in a single tablet plus amlodipine 5 mg tablet taken orally with water in the morning between 7 and 10 am.", "seriousNumAffected": 0, "seriousNumAtRisk": 61, "otherNumAffected": 0, "otherNumAtRisk": 61}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 186}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 123}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 61}]}, {"term": "Colitis ischaemic", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 186}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 123}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 61}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 186}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 123}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 61}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The Phases of this study were entered in separate tables for outcomes and the Phases for SAEs and the AEs were entered all in one table."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862 778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "C000081643", "term": "Candesartan"}, {"id": "C000077793", "term": "Candesartan cilexetil"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "CRC", "relevance": "HIGH"}, {"id": "M58172", "name": "Candesartan", "asFound": "Voice", "relevance": "HIGH"}, {"id": "M58182", "name": "Candesartan cilexetil", "asFound": "Voice", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}